{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:30:39Z","timestamp":1791304239528,"version":"4.3.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["GOA 2018"],"award-info":[{"award-number":["GOA 2018"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["ID36572"],"award-info":[{"award-number":["ID36572"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1802154N"],"award-info":[{"award-number":["1802154N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jhepr.2021.100412","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T21:02:09Z","timestamp":1637787729000},"page":"100412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8179-6802","authenticated-orcid":false,"given":"Denise","family":"van der Graaff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-302X","authenticated-orcid":false,"given":"Shivani","family":"Chotkoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0327-6304","authenticated-orcid":false,"given":"Benedicte","family":"De Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"De Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Casteleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2506-6252","authenticated-orcid":false,"given":"Jean-Pierre","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-4679","authenticated-orcid":false,"given":"Isabel","family":"Pintelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Vonghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9474-6695","authenticated-orcid":false,"given":"Wilhelmus J.","family":"Kwanten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-4714","authenticated-orcid":false,"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100412_bib1","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s12325-019-00898-6","article-title":"Pharmacological treatment for non-alcoholic fatty liver disease","volume":"36","author":"Francque","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.jhepr.2021.100412_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.mehy.2018.11.014","article-title":"The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis","volume":"122","author":"Van der Graaff","year":"2018","journal-title":"Med Hypoth"},{"key":"10.1016\/j.jhepr.2021.100412_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10620-017-4903-5","article-title":"Origins of portal hypertension in nonalcoholic fatty liver disease","volume":"63","author":"Baffy","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2021.100412_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1478-3231.2009.02136.x","article-title":"Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in\u00a0vitro and in\u00a0vivo in a rat model","volume":"30","author":"Francque","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100412_bib5","first-page":"1449","article-title":"Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis","volume":"22","author":"Francque","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100412_bib6","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/labinvest.2012.103","article-title":"Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture","volume":"92","author":"Francque","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhepr.2021.100412_bib7","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/s41374-017-0018-z","article-title":"Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats","volume":"98","author":"Van der Graaff","year":"2018","journal-title":"Lab Investig"},{"key":"10.1016\/j.jhepr.2021.100412_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032785","article-title":"Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD","volume":"7","author":"Pasar\u00edn","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jhepr.2021.100412_bib9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hep.20302","article-title":"Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice","volume":"40","author":"McCuskey","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100412_bib10","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.30294","article-title":"Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease","volume":"69","author":"Lefere","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100412_bib11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.biopha.2018.06.152","article-title":"Effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats","volume":"106","author":"Olapeju","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jhepr.2021.100412_bib12","first-page":"43","article-title":"Protective effects of celecoxib on ischemia reperfusion-induced acute kidney injury: comparing between male and female rats","volume":"22","author":"Kianian","year":"2019","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.jhepr.2021.100412_bib13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/eci.12636","article-title":"Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats","volume":"46","author":"Hsu","year":"2016","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.jhepr.2021.100412_bib14","article-title":"Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"Plos Biol"},{"key":"10.1016\/j.jhepr.2021.100412_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jcmgh.2020.04.010","article-title":"Diet reversal and immune modulation show key role for liver and adipose tissue T cells in murine nonalcoholic steatohepatitis","volume":"10","author":"Van Herck","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100412_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","article-title":"Animal models of nonalcoholic fatty liver disease","volume":"8","author":"Hebbard","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100412_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0156650","article-title":"Contribution of cyclooxygenase end products and oxidative stress to intrahepatic endothelial dysfunction in early non-alcoholic fatty liver disease","volume":"11","author":"Gonzalez-Paredes","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jhepr.2021.100412_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0163-7258(01)00126-7","article-title":"Cirrhosis of the liver and receptor-mediated function in vascular smooth muscle","volume":"89","author":"Hadoke","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2021.100412_bib19","doi-asserted-by":"crossref","first-page":"5647161","DOI":"10.1155\/2019\/5647161","article-title":"Increased serum angiotensin II is a risk factor of nonalcoholic fatty liver disease: a prospective pilot study","volume":"2019","author":"Li","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.jhepr.2021.100412_bib20","first-page":"107","article-title":"Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob\/ob male mice","volume":"30","author":"Kato","year":"2012","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jhepr.2021.100412_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12944-017-0432-7","article-title":"Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice","volume":"16","author":"Verbeek","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jhepr.2021.100412_bib22","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1038\/s41598-019-40322-1","article-title":"Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan","volume":"9","author":"Park","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100412_bib23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3892\/ijmm.2016.2674","article-title":"Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor \u03b3","volume":"38","author":"Tsujimoto","year":"2016","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jhepr.2021.100412_bib24","first-page":"811","article-title":"Celecoxib attenuates liver steatosis and inflammation in non-alcoholic steatohepatitis induced by high-fat diet in rats","volume":"4","author":"Chen","year":"2011","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jhepr.2021.100412_bib25","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/01.meg.0000231749.60889.f7","article-title":"Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency","volume":"18","author":"Barth","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100412_bib26","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1042\/CS20210549","article-title":"Endothelin receptor antagonism improves glucose handling, dyslipidemia, and adipose tissue inflammation in obese mice","volume":"135","author":"Rivera-Gonzalez","year":"2021","journal-title":"Clin Sci"},{"key":"10.1016\/j.jhepr.2021.100412_bib27","first-page":"77","article-title":"Hepatotoxicity by bosentan in a patient with portopulmonary hypertension : a case-report and review of the literature","volume":"20","author":"Eriksson","year":"2010","journal-title":"J\u00a0Gastrointest Liver Dis"},{"key":"10.1016\/j.jhepr.2021.100412_bib28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40264-015-0275-y","article-title":"Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension","volume":"38","author":"Aversa","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.jhepr.2021.100412_bib29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial","volume":"7","author":"Sitbon","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhepr.2021.100412_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1042\/CS20120030","article-title":"Update on new\u00a0aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options","volume":"123","author":"Grace","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jhepr.2021.100412_bib31","first-page":"203","article-title":"Activation of the alternate renin-angiotensin system correlates with the clinical status in human cirrhosis and corrects post liver transplantation","volume":"8","author":"Casey","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhepr.2021.100412_bib32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.27117","article-title":"Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis","volume":"60","author":"Granzow","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100412_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/gutjnl-2015-309600","article-title":"Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis","volume":"66","author":"Klein","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100412_bib34","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/j.1872-034X.2007.00165.x","article-title":"New angiotensin II type 1 receptor blocker olmesartan improves portal\u00a0hypertension in patients with cirrhosis","volume":"37","author":"Hidaka","year":"2007","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2021.100412_bib35","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3892\/etm.2017.4210","article-title":"Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and \u03b2-blocker combination therapy vs. \u03b2-blocker monotherapy for portal hypertension in cirrhosis: a meta-analysis","volume":"13","author":"Wang","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jhepr.2021.100412_bib36","doi-asserted-by":"crossref","first-page":"24155","DOI":"10.18632\/oncotarget.23816","article-title":"Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"}],"updated-by":[{"DOI":"10.1016\/j.jhepr.2024.101097","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000}}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:05:40Z","timestamp":1778904340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921001889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2589555921001889"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100412","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100412"}}